Caxton Advantage Life Sciences Fund
Overview
Caxton Advantage Life Sciences Fund is a private equity firm specializing in late-stage investments in biotechnology and pharmaceutical companies. The firm focuses on clinical development stage private and micro-cap public companies, aiming to support the growth and commercialization of innovative medical solutions. The fund's investment strategy involves providing capital to companies that are advancing promising therapies and medical technologies. By partnering with these companies, Caxton Advantage seeks to enhance their development and market presence, contributing to the advancement of healthcare. With a history of successful investments, the firm has demonstrated a commitment to fostering innovation in the life sciences sector. Its portfolio includes companies that have achieved significant milestones, reflecting the fund's expertise in identifying and nurturing high-potential opportunities in the biotechnology and pharmaceutical industries.
Investment Focus
- Late-stage biotechnology and pharmaceutical companies
- Clinical development stage private and micro-cap public companies
- Innovative medical solutions with growth potential
Portfolio Companies
Reach Caxton Advantage Life Sciences Fund directly
Verified work email, phone and LinkedIn for the full team — one spreadsheet, one payment, yours to keep.
Unlock full contacts →Frequently asked questions about Caxton Advantage Life Sciences Fund
What sectors does Caxton Advantage Life Sciences Fund invest in?
Caxton Advantage Life Sciences Fund invests in Healthcare, Pharmaceuticals and Biotechnology, and is based in New York, United States. Caxton Advantage Life Sciences Fund is listed as a private equity in the ConnectSafely investor database.
Which regions does Caxton Advantage Life Sciences Fund invest in?
Caxton Advantage Life Sciences Fund invests across United States and Canada.
What companies has Caxton Advantage Life Sciences Fund invested in?
Caxton Advantage Life Sciences Fund's portfolio includes Vivus, ArQule, Regado Biosciences, Mevion Medical Systems, ProNAi Therapeutics, Corthera, Anthera Pharmaceuticals and Sunesis.
Last updated · Source: ConnectSafely investor database
